EraCal: fishing for new obesity targets

EraCal’s phenotypic drug discovery platform takes advantage of the variety of high-throughput behavioral measurements that can be made in zebrafish to more accurately identify appetite suppressing molecules as therapeutics for obesity.

While the commercial success of GLP-1R agonists has opened up obesity as the next major market, the history of drug development for the indication is littered with failures. ...